



2025 IN REVIEW

STALLERGENES  GREER
Life beyond allergy

CONTENTS

- 04 At a glance
- 06 A conversation with Dr Andreas Amrein, Chairman and CEO

HIGHLIGHTS

- 13 Highlights
- 15 China
- 16 YOBI study
- 17 Venom supply

11



GOVERNANCE, PEOPLE AND PERFORMANCE

- 20 Strategy and vision
- 21 Four strategic pillars
- 22 Governance
- 24 People and culture
- 28 Business performance

18

ALLERGIES AND AIT, IMPROVING QUALITY OF LIFE

- 34 Allergies, an underestimated burden
- 36 Beyond symptoms: the human impact



32



40

INNOVATING FOR IMPACT

- 42 Science
- 46 Technical and pharmaceutical operations

RESPONSIBILITY

- 52 Care Beyond Allergy
- 56 Stallergenes Greer Foundation

50

PRODUCTS AND PORTFOLIO

- 60 Our products
- 62 Our portfolio




58

AT A GLANCE

Stallergenes Greer is a leading global biopharmaceutical company specialising in allergy care, through the development and commercialisation of allergen immunotherapy (AIT) products and services for the diagnosis and treatment of allergies. AIT treats the underlying cause of the allergic disease by rebalancing the immune system. It can alter the natural course of allergies and is a therapeutic class capable of modifying disease progression.

GLOBAL FOOTPRINT

Stallergenes Greer boasts a broad global footprint and extensive allergen and finished AIT product manufacturing capabilities.



Close to **400** allergens

7

manufacturing sites



1,212
employees worldwide

CARE BEYOND ALLERGY

Four pillars form the framework of our Environmental, Social and Governance programme, Care Beyond Allergy. They emphasise our responsibility both as a company and as an employer and focus on areas in which we can make a difference: society, environment, social and governance.

120+
years of expertise

STALLERGENES GREER FOUNDATION

The foundation's mission is "to create healthier futures for all" by: focusing on scientific research to bolster innovation; supporting academic initiatives to develop future generations of allergy healthcare professionals; and engaging in climate action and environmental protection to progress the prevention and treatment of allergies.



46 A presence in 46 countries including the distribution network

1.3m+ More than 1.3 million patients treated worldwide



A CONVERSATION WITH DR ANDREAS AMREIN, CHAIRMAN AND CEO

You joined Stallergenes Greer at an inflection point for the company. As you reflect on your first year leading the company, what were your main strategic priorities?

When I joined Stallergenes Greer, my immediate priority was to define a clear and ambitious strategic vision for the decade ahead. One that would provide focus, discipline and a roadmap for sustainable value creation. This required a rigorous assessment of our competitive positioning, core capabilities and the areas where we can credibly lead.

We structured our strategy around four pillars: strengthening our core business in established markets, making disciplined portfolio choices to optimise investment allocations, positioning the company for sustainable growth in the most attractive geographies, and pursuing inorganic growth.

Over the past year, we have accelerated our decision-making across both portfolio expansion and rationalisation. We have pursued targeted geographic expansion while maintaining a sharp therapeutic focus. At the same time, we have strengthened the organisation by enhancing capabilities, increasing capacity and aligning our structure with our growth ambitions.

How would you assess the company's business performance this year? What are the key achievements and challenges you've navigated?

Overall, we delivered solid performance in our key markets while making important strategic progress that strengthens our medium- and long-term outlook.

Among our key achievements were strong commercial execution in core geographies and expansion of our footprint in Asia-Pacific with concrete progress toward entering the Chinese market. Operationally, we improved efficiency across the Group and further strengthened our manufacturing backbone. The acquisition of Entomon enhanced our vertical integration and secured greater control over critical allergen extracts.

Clinically, the YOBI study in birch allergy expanded our paediatric portfolio, and we advanced medical affairs initiatives to improve physician education and patient access.

At the same time, we navigated several challenges. Pricing pressure in France remains a structural headwind. The discontinuation of Palforzia® was a difficult but necessary decision.

We are also managing market access reviews in certain geographies, including Japan.

More broadly, we continue to engage with healthcare systems and payers to ensure allergen immunotherapy is appropriately recognised and valued as a disease-modifying treatment. Securing this recognition is essential to unlocking the full potential of our category.

“We structured our strategy around four pillars: strengthening our core business in established markets, making disciplined portfolio choices to optimise investment allocations, positioning the company for sustainable growth in the most attractive geographies and pursuing inorganic growth.”

Can you share the rationale behind the discontinuation of Palforzia® and what it means for Stallergenes Greer's future in food allergy going forward?

The decision was driven by commercial and economic realities. Palforzia® demonstrated strong clinical efficacy and safety profile; however, its complex administrative and dosing requirements limited adoption in routine clinical practice and ultimately made the product economically unviable.

Following a comprehensive review, we terminated the licence agreement and discontinued commercialisation. We will continue to meet all regulatory obligations for as long as we hold the marketing authorisation and are working closely with authorities to ensure a safe and orderly withdrawal.

Importantly, this was a product decision, not a strategic exit from food allergy. In the U.S., for example, we remain the leading supplier of bulk peanut allergen extracts. We continue to focus on advancing practical, innovative solutions in both respiratory and food allergy where we can generate meaningful clinical impact and sustainable commercial value.

You have moved quickly to expand in Asia-Pacific, notably with the deal in China. How does geographic expansion fit into your growth strategy?

Geographic expansion is a central pillar of our growth strategy and is grounded in strong epidemiological and market fundamentals. Today, approximately one-third of the global population suffers from allergies, and projections suggest this could reach 50% by 2050. The addressable market is both substantial and growing.

Asia-Pacific offers particularly attractive dynamics: increasing allergy prevalence driven by urbanisation and environmental factors, expanding middle-class populations with rising healthcare spending and healthcare systems increasingly focused on preventive and disease-modifying treatments. China, as the world's second-largest pharmaceutical market, is expected to become the largest allergy market globally.

Our partnership-based model enables us to leverage local expertise, navigate regulatory pathways efficiently and access established commercial infrastructure. This approach accelerates market entry, optimises capital deployment and mitigates execution risk.



“Success will be defined by disciplined execution across commercial, portfolio and financial dimensions.”

“Our ambition is to shape and lead the evolution of allergy care, setting the benchmark for treatment efficacy, patient outcomes and commercial excellence.”

The allergen immunotherapy space is seeing new modalities, digital health integration and changing patient preferences. How are you positioning the portfolio to address these changes?

Innovation in our field must ultimately be measured by patient outcomes and clinical value, not simply by technological novelty. Established technologies are not synonymous with stagnation. In allergy care, proven platforms that deliver durable disease modification remain highly relevant.

Our approach is one of pragmatic innovation: building on validated technologies while selectively exploring emerging solutions that offer clear clinical benefits.

We are responding to evolving stakeholder expectations on multiple fronts. Patients increasingly prioritise convenience and flexibility. Physicians need improved diagnostics and biomarkers to refine patient selection and treatment protocols. Payers demand robust real-world evidence demonstrating long-term clinical and economic value. Our strategy addresses each of these requirements.

We are evaluating next-generation delivery platforms and looking into how artificial intelligence can help identify novel biomarkers and deepen our understanding of disease mechanisms. In parallel, we are exploring how monoclonal antibodies and allergen immunotherapy may be combined to enhance outcomes for patients with allergy and asthma.

Our innovation strategy remains disciplined. We prioritise opportunities aligned with our core expertise, clear unmet medical needs and realistic pathways to adoption and reimbursement.

Looking ahead, what does success look like for Stallergenes Greer?

Success will be defined by disciplined execution across commercial, portfolio and financial dimensions.

Commercially, we aim to sustain growth in our core markets while scaling effectively in high-growth regions such as Asia-Pacific and establishing a presence in additional attractive markets. We will complement organic development with external innovation and strategic partnerships that accelerate our pipeline and expand our capabilities.

From a portfolio perspective, we will maintain focus—investing selectively in high-potential products and indications supported by state-of-the-art manufacturing that ensures consistent quality and efficacy.

Financially, success means delivering sustained value creation through revenue growth, margin expansion and disciplined capital allocation.

Ultimately, our ambition is to shape and lead the evolution of allergy care, setting the benchmark for treatment efficacy, patient outcomes and commercial excellence.

To conclude, I would like to thank the Board of Directors for their confidence and strategic guidance. I am deeply grateful to our employees worldwide for their commitment, professionalism and resilience as we drive meaningful change. And I thank the healthcare professionals and patients who place their trust in Stallergenes Greer. We remain firmly committed to advancing the standard of care in allergy treatment.

HIGHLIGHTS

HIGHLIGHTS



JUNE 2025
EAACI Congress 2025
 At the annual EAACI Congress, Stallergenes Greer presents 25 scientific posters showcasing evidence from the VORAN and PRACTIS studies, assessing the sustained benefits of the Group's AIT treatments.

SEPTEMBER 2025
China Partnership for Actair®
 Stallergenes Greer and Nuance Pharma enter into an exclusive long-term partnership for the development and commercialisation of Actair® in China.



OCTOBER 2025
Positive Phase IIIb YOBI Study Results
 The YOBI study meets its primary endpoint in the paediatric population (5-17) with confirmed allergic rhinitis to birch pollen.

JANUARY 2025
Palforzia® Expanded to Toddlers
 The European Commission approves the extension of Palforzia® for treating toddlers aged 1-3 with confirmed peanut allergy, significantly broadening access to this treatment for younger patients.

APRIL 2025
CEO Appointment
 The Board of Directors appoints Dr Andreas Amrein Chief Executive Officer of Stallergenes Greer.

JANUARY 2026
Dr Andreas Amrein Elevated to Chairman and CEO
 The Board of Directors appoints Dr Andreas Amrein as Chairman and CEO, consolidating leadership and reinforcing strategic continuity as the company enters its next phase of growth.

JANUARY 2026
Entomon Acquisition
 Stallergenes Greer acquires Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and venom immunotherapy (VIT).



CHINA UNLOCKING THE WORLD'S LARGEST AIT MARKET

In September 2025, Stallergenes Greer entered into an exclusive long-term partnership with Nuance Pharma for the development and commercialisation of Actair®, our house dust mite sublingual immunotherapy (SLIT) tablet, in China.

This agreement exemplifies some of the key principles which guide our geographic expansion: prioritising markets with significant patient needs, partnering with organisations that bring complementary capabilities and remaining flexible to adapt our strategy to local markets.

A Promising Market for AIT

Allergic rhinitis, which is developing concurrently with the country's industrial and urban expansion¹, is a growing health concern in China.

Geographic studies demonstrate substantial regional variation, with adult allergic rhinitis prevalence ranging from 9.6% to close to 24%, and childhood rates averaging 9.8% in surveyed populations from China's northern and southern regions^{2,3}.

The Chinese market represents an extraordinary opportunity for allergen immunotherapy (AIT). Close to 18% of China's population suffers from house dust mite-induced allergic rhinitis⁴. Over the past five years, the number of AIT-treated patients has shown double-digit growth, and industry projections suggest the Chinese AIT market has the potential to reach €1 billion within the next decade⁵, making it the largest AIT market in the world.

Moreover, Chinese clinical guidelines currently recommend AIT as a first-line treatment for allergic rhinitis, particularly in moderate to severe cases. However, uptake remains constrained by infrastructure limitations and low awareness. Actair® addresses these barriers by offering patients a standardised tablet formulation backed by robust clinical evidence.

A Disciplined Market Entry Strategy

Actair®, which is approved by the European Medicines Agency and already available in 21 countries globally, benefits from China's early access programme in pilot zones. The programme enables patients to access the treatment ahead of full approval by the National Medical Products Administration (NMPA), while generating valuable local real-world evidence on safety profile and effectiveness.

Partnership Structure

Under the partnership agreement, Stallergenes Greer and Nuance Pharma will collaborate on the development and registration of Actair® in China, with Nuance Pharma responsible for subsequent commercialisation.

1. Zhou M., Wang H., Zhu J., et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. *The Lancet*. 2016;387(10015):251-272. doi: 10.1016/S0140-6736(15)00551-6. — 2. Wang X. D., Zheng M., Lou H. F., et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2009 to 2011. *Allergy*. 2016;71(8):1170-1180. doi: 10.1111/all.12874. — 3. Li F., Zhou Y., Li S., et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. *BMC Public Health*. 2011;11:p. 437. doi: 10.1186/1471-2458-11-437. — 4. Wang XD, et al. Prevalence and risk factors of allergic rhinitis: a meta-analysis. *Biomed Res Int*. 2018;2018:4627403 — 5. Industry market analysis and projections

YOBI STUDY: A MILESTONE IN PAEDIATRIC ALLERGY CARE

In October 2025, Stallergenes Greer reached a significant milestone with the positive results of its YOBI Phase IIIb (YOung patients and BIrch allergy) clinical study. The study assessed the safety and efficacy of birch allergenic sublingual solution in treating children and adolescents with birch pollen-induced allergic rhino-conjunctivitis, thus marking an important advancement in paediatric AIT.

A Comprehensive European Study

The YOBI study enrolled 553 children aged 5-17 years with moderate to severe birch pollen-induced allergic rhino-conjunctivitis, with or without asthma, across 64 sites in 12 European countries. The trial assessed the efficacy and safety of 300IR daily maintenance dose administered pre- and co-seasonally over two consecutive birch pollen seasons.

Addressing an Important Medical Need

Birch pollen is one of the leading triggers of allergic rhino-conjunctivitis across Europe (Biedermann et al. 2019) and remains a major contributor to the global allergy burden, with an estimated 100 million cases reported worldwide (McKenna et al. 2017).

Data from a large skin test study conducted under the auspices of the Global Asthma and Allergy European Network (GA2LEN) showed that clinically relevant sensitisation to birch pollen affects nearly one in five individuals (19.6%) in Europe, with marked geographical variation, ranging from 4.0% in France to 49.1% in Denmark (Burbach et al. 2009).

In addition to environmental exposure, individual risk factors play a significant role. A positive family history and early sensitisation are recognised predictors of the development of allergic disease and asthma from childhood through early adulthood (Lau et al. 2019). Moreover, exposure to high concentrations of birch pollen during infancy has been associated with an increased likelihood of subsequent sensitisation to birch and a higher risk of developing allergic asthma (Kihlstrom et al. 2002).

A Strategic Milestone

The positive outcome of this large clinical study completes our paediatric development programme in respiratory allergies, and strengthens the body of evidence supporting our sublingual liquid treatments.

SECURING CRITICAL VENOM SUPPLY FOR LIFE-SAVING TREATMENTS

In January 2026, Stallergenes Greer acquired Entomon s.r.l., an Italian company which produces certified stinging-insect venom extracts used in life-saving treatments. Entomon is the only European entity capable of extracting pure venom from Hymenoptera insects (bees, wasps, and hornets).

Addressing a Critical Medical Need

Hymenoptera venom allergies represent the leading cause of anaphylaxis in adults¹. These allergies affect a significant portion of the population, with sensitisation rates ranging between 9.3% and 28.7% among the public, and more than half of all people will experience an insect sting at least once during their lifetime^{2,3}.

While most insect stings result in mild, localised reactions, individuals with venom allergies can experience life-threatening anaphylaxis from a single sting. In Europe, Hymenoptera venom allergy is responsible for 48.2% of adult anaphylaxis cases and 20.2% of cases in children⁴.

Understanding Anaphylaxis and Venom Allergies

Anaphylaxis is a rapid and severe allergic reaction which affects multiple organs simultaneously. When triggered by insect venom, symptoms include constricted airways, drops in blood pressure, rapid pulse, dizziness and loss of consciousness. In the most severe cases, it can be fatal.

Venom allergies are particularly unpredictable. Individuals who experience mild reactions to initial stings may suddenly develop life-threatening anaphylaxis after subsequent stings. Proper diagnosis and preventive treatment are essential to improve quality of life for patients with identified systemic risk.

A Recognised Therapeutic Option

Venom immunotherapy (VIT) is the only proven treatment to modify the natural course of venom allergy and prevent systemic reactions.

Because venoms differ between Hymenoptera species, high-quality, species-specific venom extracts are critical for accurate diagnosis and effective therapy.

Strengthening the Supply Chain

The acquisition complements our existing portfolio and builds on our well-established position in VIT with Albey®, which consists of standardised purified extracts from honeybee, yellow jacket and paper wasp species. These extracts hold marketing authorisations in France, Italy, Australia and New Zealand, providing proven treatment options for patients in multiple countries.

It also builds on our existing partnerships and supports a diversified model for VIT components, while further strengthening long-term access to these critical raw materials for patients who depend on VIT.



1. Hymenoptera (bee and wasp) Stevens et al. Recent insights into the mechanisms of anaphylaxis. *Curr Opin Immunol.* 2023 Apr;81 – 2. Bilò, M. B., Pravettoni, V., Bignardi, D., Bonadonna, P., Mauro, M., Novembre, E., ... & Pastorello, E. A. (2019). Hymenoptera venom allergy: management of children and adults in clinical practice. *Journal of investigational allergology & clinical immunology*, 29(3), 180-205. – 3. Golden, D. B., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., ... & Wallace, D. (2017). Stinging insect hypersensitivity: a practice parameter update 2016. *Annals of Allergy, Asthma & Immunology*, 118(1), 28-5 – 4. Worm, M., Moneret-Vautrin, A., Scherer, K., Lang, R., Fernandez-Rivas, M., Cardona, V., Kowalski, M. L., Bilò, M. B., Muraro, A., & Beyer, K. (2014). First European data from the network of severe allergic reactions (NORA). *Allergy*, 69(10), 1397-1404. <https://doi.org/10.1111/all.12475>

**GOVERNANCE,
PEOPLE AND
PERFORMANCE**

STRATEGY AND VISION

OUR VISION

Leading innovative patient care to enable long-lasting allergy relief.



OUR PURPOSE

Stallergenes Greer is committed to offering allergy patients a broad portfolio of innovative products for the diagnosis and treatment of allergies. We aspire to be the preferred partner for healthcare professionals and scientific bodies in shaping the standard of care in allergy therapeutics.

ENSURING GROWTH BENEFITS ALL STAKEHOLDERS

Our strategy explicitly incorporates environmental, social and governance considerations as foundational elements of our long-term vision. We recognise that sustainable growth requires balancing the needs of patients, employees, communities and our planet whilst delivering value to all stakeholders.

FOUR STRATEGIC PILLARS

Stallergenes Greer's 2035 vision rests upon four strategic pillars; each addresses distinct market opportunities whilst contributing to the Group's competitive advantage.

1. STRENGTHEN OUR CORE BUSINESS

Secure and strengthen our established leadership positions

We have built strong positions in the markets in which we operate. To maintain and strengthen these positions, we shall actively manage the lifecycle of our products, develop regulatory foresight and invest in innovation whilst creating a platform for future growth.

Continue lifecycle management | Expand paediatric indications | Deploy digital adherence solutions

2. EXPAND CORE OFFERING

Broaden our AIT portfolio to address unmet needs and capture market share in high-value segments

We are committed to enhancing our product portfolio for the benefit of patients and healthcare professionals. We will expand our market presence through the combination of innovation and strategic portfolio additions.

Develop new products | Pursue strategic partnerships | Enhance portfolio through innovation

3. EXTEND GEOGRAPHIC PRESENCE

Extend our presence in untapped and high-growth markets through partnerships and local strategies

Whilst Europe and the U.S. remain core markets, Asia offers exceptional growth opportunities and strategic importance for long-term value creation. We shall focus on establishing leadership positions in key growth markets.

Launch in China with partners | Consolidate Nordic success | Explore and enter new geographies

4. PURSUE INORGANIC GROWTH

Position Stallergenes Greer at the forefront of allergy care

To strengthen our competitiveness, we shall complete and broaden our portfolio by exploring additional and adjacent areas whilst maintaining AIT leadership.

Explore adjacencies | Broaden and complete portfolio | Invest in next generation therapeutics

TRENDS IN ALLERGIES

The global allergy market is experiencing substantial growth, driven by the rising prevalence of allergies linked to climate change and urbanisation, increasing healthcare expenditure in key markets worldwide, the emergence of novel therapeutic solutions (notably biologics), growing patient and physician awareness of treatment options and enhanced diagnostics.

Allergen immunotherapy (AIT) continues to evolve with significant shifts in treatment preferences, geographic opportunities and delivery mechanisms that we are uniquely positioned to address.

ORGANISATIONAL READINESS

Achieving our 2035 Vision also requires new organisational capabilities across multiple dimensions. We are systematically building the skills, systems and culture necessary to execute our strategy with excellence in an increasingly complex and competitive environment.

GOVERNANCE



THE BOARD OF DIRECTORS

Stallergenes Greer is governed by a Board of Directors responsible for shaping and steering the Group's strategic direction.

- Dr Andreas Amrein, Chairman and CEO
- Nithya Desikan, Director
- Steven Rotman, Director
- Frédéric Boder, Director

THE EXECUTIVE COMMITTEE

Led by the Chairman and CEO, the Executive Committee is responsible for managing the Group's development and performance.



At March 31, 2026. From left to right: Dr Silvia Scurati, Chief Medical Officer; Dr Babette Güldenpfennig, Senior Vice President Business Development, Licensing and M&A; Nicola Lamacchia, Chief Financial Officer; Dominique Pezziardi, Executive Vice President International Commercial Operations; Dr Andreas Amrein, Chairman and CEO; Tibor Nemes, Executive Vice President Americas; Frédéric Chapuis, Senior Vice President Global Products Strategy; Dr Julien Storai, Senior Vice President Pharmaceutical Operations; Valérie Benhamou, General Counsel; Jérôme Tilly, Senior Vice President, Human Resources.

SHAREHOLDING

Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by the B-FLEXION group.

B-FLEXION is a private, entrepreneurial investment firm with an approach that combines multi-generational family values,

a true entrepreneurial mindset and institutional private equity disciplines.

B-FLEXION makes direct and principal investments in operating businesses across biotech, therapeutics, diagnostics, physician practice management, and more. It also seeds or

acquires (and then builds) Investment Partnerships, joining with high calibre, entrepreneurial investment teams across a range of asset classes.

Chaired by Ernesto Bertarelli, B-FLEXION has offices across Europe and in the U.S.

OUR VALUES

Stallergenes Greer is guided by five core values. They form the bedrock of our company culture, shape our behaviours and define the principles we adhere to.



RESPECT

Accept and appreciate others for who they are, with kindness, courtesy and consideration.



AGILITY

The ability to adapt quickly to meet company objectives in a complex and changing environment.



PATIENT CARE

Accompanying and supporting allergic patients, guided by excellence, sharing and the commitment to improve their quality of life.



INTEGRITY

Acting with honesty, ethics, loyalty and transparency, no matter the challenges or the obstacles.



DEDICATION

Committing oneself with passion and involvement to the fulfilment of the company's mission, with a strong sense of purpose and always striving to surpass oneself.

PEOPLE AND CULTURE



OUR ABILITY TO INNOVATE, ADAPT AND DELIVER FOR PATIENTS RESTS ON A STRONG FOUNDATION: OUR PEOPLE AND THE CULTURE WE BUILD TOGETHER. IN 2025, STALLERGENES GREER ADVANCED CRITICAL INITIATIVES IN TALENT MANAGEMENT, VALUES INTEGRATION AND LEADERSHIP DEVELOPMENT TO SUPPORT THE GROUP'S LONG-TERM SUCCESS.

STRENGTHENING BUSINESS CONTINUITY THROUGH TALENT

In 2025, Stallergenes Greer transformed its approach to talent management with a comprehensive, company-wide strategy designed to identify critical expertise, secure key positions and ensure continuity of our operations. By placing the right people in the right roles at the right

time, we are building the foundation for sustainable performance and long-term success.

Leading this strategic initiative is our newly appointed Talent Director, a position filled through internal promotion, reflecting our belief in developing talent from within.



THE VALUES THAT GUIDE US

Our values are more than words: they are the foundation of how we work, lead and grow together. In 2025, Stallergenes Greer embedded these values throughout our Human Resources cycle, linking them directly to role expectations and performance standards. This integration creates a unified framework that shapes

behaviours, guides leadership practices and drives individual development, ensuring every action aligns with our corporate culture and serves our stakeholders, from patients and healthcare professionals to partners and colleagues.

“Patient care means being mindful that everything we do impacts patients, and that we provide solutions enabling them to live more normal lives.”

LIVING OUR VALUES



Jennifer Hryniw, General Manager Canada, based in Dutton (Ontario), shares how Patient Care shapes her day-to-day experience at Stallergenes Greer.

“Patient care means being mindful that everything we do impacts patients, and that we provide solutions enabling them to live more normal lives. This involves actively advocating for and supporting patients’ interests, building trust, and demonstrating commitment to improving their quality of life. This value guides everything I do and must be the lens through which we all view our work – ensuring the right product is available at the right time for the right patient. Ultimately, patient care is about remembering our purpose. If we lose sight of this, all our other values – respect, agility, integrity, dedication – may lose their meaning.”



DIGITAL HR FOR ENHANCED WORKFORCE MANAGEMENT

At Stallergenes Greer, training is accessible to all employees across the Group through structured development programmes which support continuous skills growth. Our “One HR” platform brings together all essential Human Resources processes: performance management, career planning and key employee information. This centralised digital ecosystem delivers consistent, streamlined support at every stage of the employee journey, making development more accessible and career progression more transparent.



98%

Training for All: 98% of employees participated in training programmes in 2025

“Agility is the ability to adapt swiftly to market changes while remaining flexible enough to evolve strategy.”

LIVING OUR VALUES



Zeynep Graham, Marketing Director, based in Dusseldorf (Germany), shares her perspective on Agility:


“Agility is the ability to adapt swiftly to market changes while remaining flexible enough to evolve strategy. It involves being innovative and efficient in processes such as drug development, manufacturing and distribution across our markets. In Germany, we have the capability to seize market opportunities and adapt quickly, making the right decisions at the right time, this perfectly embodies the value of agility. Ultimately, for me, agility means being open-minded and willing to take calculated risks. It’s about having a “let’s see” mindset and being ready to try new things.”

DEVELOPING LEADERS AT EVERY LEVEL

Strong leadership at every level is essential to our success. In 2025, we notably launched several targeted development programs designed to build leadership excellence across the Group, including:

- Propel: equipping first-level managers with essential leadership skills.
- Lead Up: advanced leadership training for managers of managers.
- Impactful Communication: building communication skills that drive results.

These programmes ensure our leaders are equipped not just to manage, but to inspire, guide and deliver on our strategic objectives.



ACTING ON EMPLOYEE FEEDBACK

Following our employee survey in 2024, we developed and implemented targeted action plans based on the input of our employees. Some of the actions already taken include broader access to online training programmes, more

leadership webcasts and dedicated communication on internal screens.

In line with our commitment to continuous improvement, the next engagement survey will be conducted in 2026 to measure progress and identify where we can do even better.



56%

Women in Leadership: 56% of our organisation's leaders are women

BUSINESS PERFORMANCE

IN 2025, STALLERGENES GREER DELIVERED ROBUST PERFORMANCE DRIVEN BY COMMERCIAL EXCELLENCE, IMPACTFUL NEW PRODUCT AND INDICATION LAUNCHES, BROADER PATIENT ACCESS TO ALLERGEN IMMUNOTHERAPY (AIT) AND GEOGRAPHIC EXPANSION. TOGETHER, THESE ACHIEVEMENTS STRENGTHEN OUR FOUNDATIONS AND POSITION US WELL FOR FUTURE GROWTH

FRANCE Innovation and Excellence in Execution

France confirmed its core role within the Group in 2025, delivering strong performance across the portfolio. Favourable market dynamics, combined with disciplined commercial execution, drove results, while market demand continued to expand due to increasingly severe allergies and improved access to allergy specialists.

Our digital solutions, iPUMP® and Ordoizzy®, continued to gain strong adoption, reinforcing our commitment to digital patient support. We published results from the SPEED real-world evidence study on iPUMP®, which confirmed significant impact in patient adherence.

Staloral® Cat 300 IR maintained its momentum, achieving double-digit growth in new patients and confirming the unmet medical need within this patient population.

Albey® reached an important regulatory milestone with reimbursement approval for Polistes (wasp) venom, completing our comprehensive venom portfolio. Volumes grew substantially as more patients gained access to treatment. The extension of Albey® availability in pharmacies has significantly improved accessibility for both physicians and patients, removing a longstanding barrier to care.



GERMANY Growth Through Excellence

In 2025, the Phase III YOBI study (YOung patients and BIrch allergy) successfully met its primary endpoint. The study assesses the efficacy of birch allergenic sublingual solution in children and adolescents aged 5–17 years with birch pollen-induced allergic rhino-conjunctivitis. This clinical milestone confirms this treatment as a validated treatment option for children.

Stallergenes Greer was once again the fastest-growing company in the German AIT market, driven by the continued success of the Orylmyte® launch. We significantly increased our share of voice by establishing a dedicated team of medical advisors to navigate evolving market dynamics as products progress through the Therapy Allergen Ordinance (TAO) regulatory process.

The TAO framework represents a significant opportunity for Stallergenes Greer, as our treatments are supported by robust clinical evidence. With 2026 expected to be the final year for approval applications, non-registered AIT products may exit the German market in the near future, further strengthening the competitive position of approved therapies.

THE NETHERLANDS AND NORDICS

Positive momentum Amid Evolving Market Dynamics

The Netherlands and Denmark showed encouraging signs of market evolution as payers and healthcare authorities increasingly recognise the clinical and economic value of AIT. This has led to improved market conditions compared to competitors. While the reimbursement landscape remains complex and treatment protocols continue to face close scrutiny, the overall trajectory is gradually improving. Our Norwegian operations demonstrated very strong success, providing a positive model for the broader Nordic region.



ITALY Improving Patient Access in Italy

Italy delivered double-digit growth in 2025, supported by a major patient-access milestone with the approval of the improved national reimbursement for Oralair®. This achievement represents an important step forward in a market where access to AIT has historically been challenging. We continue to work closely with allergologists and healthcare institutions to further expand treatment availability and advocate for broader recognition of AIT's therapeutic value.

In parallel, the Italian affiliate accelerated the relaunch of the Albey® venom portfolio, building on its well-established clinical use and strong endorsement from the allergology community. This initiative further strengthens our position in the management of severe allergic conditions.

SPAIN Success in a Changing Regulatory Landscape

Spain is undergoing a comprehensive regularisation process for allergen-based medicines, and we are progressing with the registration of our full Named Patient Product (NPP) portfolio. This regulatory transformation creates a strategic opportunity to position Staloral®, the world's leading SLIT treatment, as well as Albey®, our standardised purified venom immunotherapy extracts, within the registered specialty category.

Throughout 2025, we continued to gain market share through disciplined execution and strengthened medical capabilities. The appointment of a new Medical Director in Spain has reinforced our commitment to scientific excellence and medical education, further deepening our engagement with the Spanish allergology community. Looking ahead, in 2026 we plan to pilot iPUMP®, our connected assistant for sublingual liquid AIT, in Spain following its proven success in France. This digital innovation is designed to support both patients and physicians by improving adherence to personalised treatment protocols.



BUSINESS PERFORMANCE

CHINA

Expanding Access


In September 2025, Stallergenes Greer entered into an exclusive long-term partnership with Nuance Pharma for the development and commercialisation of Actair®, our house dust mite sublingual immunotherapy (SLIT) tablet, in China. Registration is progressing in line with plan.

POLAND

Rapid Market Development

In 2025, the Polish market experienced a significant improvement in patient access following the reimbursement of our complete sublingual immunotherapy (SLIT) portfolio which was progressively introduced. Although the new reimbursement framework had not yet been in place for a full year, Stallergenes Greer delivered strong momentum across its sublingual treatments for house dust mite, grass and birch allergy Staloral®, Actair® and Oralair® treatments.

This broad allergen coverage, combined with favourable reimbursement conditions, strengthens our competitive positioning and provides a solid foundation for sustained growth in this important market.



AUSTRALIA Relaunching SCIT Leadership

Australia delivered double digit growth in 2025, further extending our market leadership in both the house dust mite and grass pollen tablet markets.

Alustal® HDM and Alustal® 5G, our subcutaneous allergen immunotherapy (SCIT) solutions, were successfully relaunched as the only registered SCIT products in Australia, enabling complementary SCIT and SLIT offerings across the country's two key allergens (house dust mites and grass pollen).

Albey® venom portfolio for Hymenoptera venom allergy was also relaunched in 2025 after successful price increases from the Pharmaceutical Benefits Advisory Committee, supported by key stakeholders, building upon its long-standing clinical experience and support from the allergy community.

UNITED STATES

Strengthening Market Leadership

Stallergenes Greer continued to strengthen its position as the market leader in the U.S., holding a 55% market share. While the overall U.S. AIT market declined throughout the year, our strong volume growth reflects the effectiveness of our commercial strategy and competitive positioning.

We observed a strong rise in pharmacy prescriptions for sublingual allergen immunotherapy (SLIT), notably for food allergens. Physicians are increasingly ordering allergen extracts for SLIT across the affiliate's portfolio of 93 food allergens available for both diagnostics and treatment.

Following the publication of an independent university-led clinical study on the use of SLIT for peanut allergy, published in February 2024, physicians began using our extracts for peanut, cashew and walnut allergies. These physicians prefer our ready-to-use extracts, through our pharmacy, rather than preparing their own formulations, validating our educational approach and product value proposition.



Direct-to-Patient Initiative

We are developing and launching a comprehensive non-branded educational direct-to-patient/physician omni-channel campaign in the U.S. Our ambition is to differentiate AIT as a value-driven treatment complementing symptomatic therapies, while highlighting its potential benefits in patient care. Through a creative, specific and targeted omni-channel strategy, we aim to drive more patient referrals to allergists, recapture and grow market share and increase overall demand for AIT.




San Diego: A Strategic Asset

Our San Diego operations, which have seen investments in advance equipment such as semi-automated precision filling equipment, produce significant volumes of product with high efficiency and are a significant asset for the Group with strong value creation within our global manufacturing network. Throughout the year, the site broadened its product offering capabilities and is in a position to support portfolio expansion to meet growing global market demand.

**ALLERGIES AND AIT,
IMPROVING
QUALITY OF LIFE**

Allergies, an underestimated burden

Allergic conditions have shown a persistent upward trend across more than five decades¹, affecting populations in both industrialised nations and emerging economies. Projections indicate that the global burden could reach several billion affected individuals by mid-century². These disorders create substantial challenges for patients, medical infrastructure and public healthcare systems.



Allergic rhinitis affects

10 to
30%

of the population worldwide¹

As the burden of allergic diseases continues to grow, ensuring appropriate and effective management becomes increasingly critical. Allergen immunotherapy (AIT) is recommended when allergen avoidance and symptomatic treatment are insufficient in accordance with confirmed immunoglobulin E sensitisation and the product's approved indications.

The Scale of Impact Across Key Markets

Despite millions of eligible candidates, current treatment rates with AIT remain low, with studies suggesting that fewer than 10% of qualifying patients actually receive this disease-modifying therapy, highlighting substantial untapped market potential.

United States

In the U.S. alone, seasonal allergic rhinitis affected roughly 81 million Americans. This figure represents about one-quarter of the adult population (67 million) and nearly one-fifth of children (14 million)^{3,4}. The cost of nasal allergies across the U.S. is estimated between USD 3 billion and USD 4 billion each year⁵.

Europe

In the European region more than 150 million people live with an allergic condition. In the European Union alone avoidable indirect costs for patients insufficiently treated for allergy range between €55 and €151 billion p.a. due to absenteeism and presenteeism⁶.

China

Approximately 200 million individuals in China suffer from allergic rhinitis⁷. Nearly 18% of China's population suffers from HDM-induced allergic rhinitis and AIT has the potential to reach €1 billion within 10 years, making it the largest AIT market in the world⁸.

The Market Opportunity

Despite the large patient population and proven clinical benefits, the AIT market remains significantly underpenetrated. With 500 million people worldwide currently affected by allergic rhinitis⁹, market growth is expected to accelerate as awareness increases, access to specialists improves and personalised treatment options expand.

Sensitisation rates in children approach¹

40 to
50%

1. World Health Organization. White Book on Allergy 2011-2012 Executive Summary. By Prof. Ruby Pawankar, MD, PhD, Prof. Giorgio Walter Canonica, MD, Prof. Stephen T. Holgate, BSc, MD, DSc, FMed Sci and Prof. Richard F. Lockey, MD. — 2. EAACI Global atlas of Allergy 2014 — 3. Ng, A.E. & Boersma, P. (2023). NCHS Data Brief, no 460: Diagnosed allergic conditions in adults: United States, 2021. National Center for Health Statistics. <https://dx.doi.org/10.15620/cdc.122809> — 4. Zablotsky, B., Black, L.L., & Akinbami, L.J.(2023). NCHS Data Brief, no 459: Diagnosed allergic conditions in children aged 0-17 years: United States, 2021. National Center for Health Statistics. <https://dx.doi.org/10.15620/cdc.123250> — 5. Tkacz, J. P., Rance, K., Waddell, D., Aagren, M., & Hamnerby, E. (2021). Real-World Evidence Costs of Allergic Rhinitis and Allergy Immunotherapy in the Commercially Insured United States Population. *Current Medical Research and Opinion*, 37(6), 957-965. <https://doi.org/10.1080/03007995.2021.1903848> — 6. EAACI Advocacy Manifesto, version June 2015 — 7. Wang Y, Gao Z, Lv H, Xu Y. Online public attention toward allergic rhinitis in Wuhan, China: Infodemiology study using Baidu index and meteorological data. *Front Public Health*. 2022;10:3568 — 8. Zhang Y, Zhang L. Increasing prevalence of allergic rhinitis in China. *Allergy Asthma Immunol Res* 2019;11:156-69. — 9. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. *Allergy*. 2008;63(Suppl 86):8-160 2



Beyond symptoms: the human impact

Allergy affects millions of people worldwide, yet its true burden is often underestimated. Far beyond the inconvenience of a runny nose or itchy eyes, allergic disease can disrupt sleep, limit productivity, restrict daily activities and, if left untreated, progress to serious chronic conditions such as asthma.

AIT: A disease-Modifying Treatment

Allergy is a disorder of the immune system which reacts to a normally harmless foreign substance such as house dust mites, pollens or certain foods. In people with allergies, the immune system produces antibodies that identify a particular allergen as harmful following contact, ingestion or inhalation. The immune system's reaction can cause inflammation of the eyes, skin, sinuses, respiratory airways, digestive system and may lead to anaphylaxis.

Allergen immunotherapy (AIT) represents a key "early intervention" strategy precisely because it modifies disease trajectory rather than alleviating symptoms. Leading clinical guidelines emphasise that AIT can alter the natural course of allergic disease¹, delivering sustained benefits beyond treatment cessation, including reduced asthma risk and potential prevention of new sensitisations².

The Hidden Burden

Allergic rhinitis extends far beyond "just symptoms". The condition is associated with significant multimorbidity, notably asthma, as well as sleep disruption and reduced productivity. Respiratory allergy organisations have documented a considerable disease burden and widespread undertreatment across patient populations³.

The connection to asthma development is particularly concerning. People with allergic rhinitis are three times more likely to develop asthma than other people, and patients with house dust mite-induced allergic rhinitis have a substantially higher risk of developing asthma than those whose allergic rhinitis is caused by grass pollen⁴.

Prevention: The Most Compelling Evidence

The preventive effect of AIT is most pronounced when treatment is initiated in appropriately selected patients and is maintained for adequate duration.

EAACI prevention guidance recommends a three-year course of subcutaneous or sublingual immunotherapy in children and adolescents with moderate-to-severe allergic rhinitis (particularly to grass or birch pollen) and it may reduce the risk of developing asthma with clinical benefits which may persist beyond treatment duration⁷.

Why Treatment Matters

AIT is associated with benefits on patient quality of life including sleep quality and less limitations on everyday activities.

THE AIT JOURNEY EXPLAINED

Diagnosis The specialist physician determines candidacy for AIT based on test results and response to symptomatic therapy. This treatment may also be considered for patients with less severe allergic rhinitis who wish to benefit from its long-term effects⁵.

Treatment planning An individualised treatment protocol is developed to select the administration route (subcutaneous injection (SCIT) or sublingual tablets/drops (SLIT)), review treatment duration, costs, potential adverse reactions and anticipated clinical outcomes.

Escalation period Treatment begins by gradually introducing the patient's body to allergens, with doses incrementally escalated over a 3–6-month period until the maintenance dose is reached. Close monitoring for adverse reactions is critical throughout this escalation period.

Maintenance phase After reaching the maintenance dose, the patient transitions to ongoing treatment. This extended phase continues for three to five years. Many patients begin feeling relief from their symptoms within the first year of treatment. AIT delivers sustained benefits beyond treatment cessation⁶.

1. Add Roberts et al EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. *Allergy*. 2018 Apr;73(4):765-798. — 2. Buta et al Real-world evidence of allergen immunotherapy. *Curr Opin Allergy Clin Immunol*. 2024 Dec 1;24(6):529-535, Batard T, et al. Allergen Immunotherapy for the Prevention and Treatment of Asthma. *Clin Exp Allergy*. 2025 Feb;55(2):111-141 — 3. Bousquet et al Allergic rhinitis Nature Review disease Primer 2020 and Akdis, C. A., Hellings, P. W., & Agache, I. (Eds.) (2015). *Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis*. European Academy of Allergy and Clinical Immunology. — 4. Tohidinik WAO 2019; Linneberg 2002 — 5. Roberts et al EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. *Allergy*. 2018 Apr;73(4):765-798. — 6. Alvaro-Lozano et al. EAACI Allergen Immunotherapy User's Guide. *Pediatr Allergy Immunol*. 2020 May;31 Suppl 25(Suppl 25):1-101 — 7. EAACI guidelines on allergen immunotherapy: Prevention of allergy. *Pediatric Allergy and Clinical Immunology* 2017 Dec;28(8):728-745 https://hub.eaaci.org/resources_guidelines/eaaci-guidelines-on-allergen-immunotherapy-prevention-of-allergy/?utm

Prof Dr med Boris Haxel

DIRECTOR OF THE DEPARTMENT OF OTOLARYNGOLOGY (ENT), HEAD & NECK SURGERY
SCHWARZWALD-BAAR KLINIKUM VILLINGEN, GERMANY

"Many of my patients are severely affected by allergic diseases. It's not just trivial hay fever or a runny nose; these individuals have a significantly reduced quality of life. Allergies can have a negative effect on sleep quality, cognitive function, work productivity and overall daily functioning. I see patients whose allergies limit their ability to exercise outdoors, participate in social activities, or even maintain focus at school or work.

For these patients it is important to start treatment as early as possible, before secondary diseases such as bronchial asthma develop. We know from clinical evidence that allergies tend to progress along what we call the "allergic march." If left untreated, what starts as allergic rhinitis can advance to more serious conditions such as asthma. Early intervention can prevent this progression and reduce the risk of developing chronic inflammatory conditions, recurrent sinusitis, or sleep-disordered breathing.

Symptomatic treatments provide relief for many patients, but they have a short-term effect. Once the medication wears off the symptoms return because the underlying immune dysfunction isn't addressed.

Allergen immunotherapy is a disease-modifying treatment that works at a causal level. We administer gradually increasing doses of the specific allergen to the patient on a regular basis, typically over a period of at least three years. This process can lead to immunological tolerance, meaning the patient's immune system no longer reacts as strongly, and sometimes not at all, to the allergen. What's particularly valuable is that patients can expect long-term improvement in their quality of life, prevention of chronic diseases and symptom control that persists well beyond the treatment period."



Simon

LIVING WITH MULTIPLE ALLERGIES, CANADA

"I have two main allergies: house dust mites and pollen. But I am also allergic to dust itself, and to cat and dog hair. I've had these allergies since childhood, and ironically, I still own a cat! My house isn't ideal: between potential mould, dust mites and cat hair... it's a disaster.

The intensity of my symptoms depends enormously on where I'm living. In Canada, it was better, the dry winter air helped tremendously. Then I moved to the U.K. and had many asthma attacks because my house was riddled with dust mites. Since moving to France, and living in an old house, my allergies have worsened.

What began as mild symptoms during pollen season gradually escalated. At first, it wasn't much. A week during pollen season where I'd struggle to breathe, then it would pass. Each year it returned for one week, then for two weeks.

Then one summer, it never stopped. Every night, I couldn't breathe properly. And one morning at six o'clock, after a severe attack, I ended up in A&E.

The turning point came after years of worsening symptoms. I started seeing specialists who prescribed desensitisation treatment. Now, I always carry my inhaler.

Daily life requires constant anticipation. There are periods when it's manageable, and others when it's complicated. But I've noticed something: at the seaside, I feel better. The air quality makes a real difference.

It's truly exhausting. But I manage."



Béatrice

VETERINARY SURGEON, FRANCE

"I am a veterinary surgeon specialising in dogs and cats.

When I was little, I had a cat and used to go pony riding, so I think my interest in animal care came from there. I am a veterinarian today because it is an intellectually fascinating profession that also requires a certain manual dexterity.

Veterinarians do many different things, our work is very varied and highly stimulating.

When I started developing allergies to cats, they manifested as recurring colds progressing to sinusitis.

For me, it's primarily cat saliva that triggers the allergic reaction. Initially, my allergic episodes occurred during consultations, causing difficulty breathing deeply.

I would become breathless even without any physical effort, simply from being close to a cat.

Performing dental scaling procedures on cats provoked the worst symptoms.

During one period, I had many cats under my care for dental problems. Throughout these lengthy dental procedures, I could feel myself struggling to inhale properly, and I was forced to take bronchodilators just to complete the treatment, or at the very least, to recover normal, calm breathing by the end of the procedure.

If you're allergic to cat dander, it's genuinely important to take charge of your health, seek proper follow-up care and get treatment."



INNOVATING FOR IMPACT

SCIENCE FOR THE REAL-WORLD



IN 2025, STALLERGENES GREER CONTINUED TO ADVANCE ALLERGEN IMMUNOTHERAPY (AIT) THROUGH STRATEGIC CLINICAL DEVELOPMENT, ENHANCED SCIENTIFIC LEADERSHIP, OPERATIONAL EXCELLENCE AND RESEARCH COLLABORATIONS. OUR INTEGRATED APPROACH CONTRIBUTES TO EXPANDING ACCESS TO INNOVATIVE TREATMENTS FOR PATIENTS WORLDWIDE.



EXPANDING INDICATIONS AND TERRITORIES THROUGH DATA GENERATION

Our commitment to evidence-based medicine drove significant progress in clinical development across multiple markets and patient populations in 2025.

conjunctivitis, and marking an advancement in paediatric AIT.

China Market Entry: REACH Clinical Trial

We initiated our REACH clinical trial to support the entry of Actair® in the Chinese market. The pre-Investigational New Drug submission was completed in November 2025, and we are working with our partners to successfully execute the study in one of the world's largest healthcare markets.

YOBI Study: A Landmark Clinical Achievement

Stallergenes Greer reached a significant milestone with the completion of its YOBI Phase IIIb (YOung patients and Blrch allergy) clinical study. The study met its primary endpoints, demonstrating the efficacy and favourable profile of Staloral® Birch in treating children and adolescents with birch pollen-induced allergic rhino-



INCREASING SHARE OF VOICE THROUGH SCIENTIFIC LEADERSHIP

Stallergenes Greer's scientific presence was strong in 2025, establishing thought leadership through strategic engagement at medical congresses and innovative medical education initiatives.

Immunology and Allergy (ASCI) alongside multiple national congresses.

Medical Education and Publications

Beyond congress presentations, we expanded our educational impact through digital platforms and peer-reviewed publications. Three comprehensive medical education modules were supported through unrestricted educational grants for the Xpeer platform, providing healthcare professionals with evidence-based learning resources. We also sponsored educational modules with Medscape and other digital channels, aimed at increasing allergy awareness among broader medical audiences.

A Strong Scientific Presence

The European Academy of Allergy and Clinical Immunology (EAACI) congress showcased our scientific excellence with an unprecedented presence: 25 abstracts presented, two company sponsored symposia and one award received.

Our regional engagement was equally robust, with significant presentations at the: American Academy of Allergy, Asthma & Immunology (AAAAI); Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI); Australasian Society of Clinical





PROCESS EFFICIENCY: MUTUALISING EFFORTS FOR BETTER COMPLIANCE

Recognising that operational excellence is also at the core of scientific advancement, we made significant strides in harmonising processes across our global organisation.

Global Pharmacovigilance Database

A landmark achievement in 2025 was the

implementation of a unified global pharmacovigilance database, “One PV”, integrating data from North American, European and international markets. This consolidation into a single system transforms our ability to monitor product safety, ensure regulatory compliance and respond swiftly to emerging safety signals.

ENHANCED CROSS-FUNCTIONAL COLLABORATION

By establishing shared processes and standards, we are creating a more agile and responsive organisation capable of meeting the complex demands of global pharmaceutical regulations. This collaborative approach strengthens our collective ability to serve patients and healthcare professionals worldwide.

Medical Science Liaison: Strengthening Scientific Exchange

The Medical Science Liaison initiative is a cornerstone of our medical strategy. It fundamentally transforms how we engage with key external experts and measure scientific impact. Key performance indicators will be established to provide visibility into the quality and impact of our scientific exchanges. This structured approach will enable systematic monitoring of scientific interactions while ensuring alignment.



SHAPING THE FUTURE OF ALLERGY THROUGH COLLABORATIONS

We continue to strengthen research collaborations to advance the understanding of the pathophysiology of allergic diseases and immune responses to allergen immunotherapy, working with world-class organisations such as Imperial College London (U.K.), Monash University and Alfred Hospital (Melbourne, Australia). In parallel, we are advancing AI-driven biomarker discovery to deepen our understanding of disease mechanisms and support more targeted, precision-medicine decision-making.

Building on these partnerships, our collaboration with the University of Katowice (Poland) has progressed, focusing on the combined use of

monoclonal antibodies and AIT in patients with allergies and asthma. This work aims to generate deeper insights into the potential synergistic effects of this therapeutic approach and to support the development of more targeted and effective treatment strategies.

Our integrative approach not only enhances disease characterisation but also paves the way for the development of more precise and personalised strategies for patient care. By leveraging these innovations, we can improve early detection, enhance therapeutic interventions and empower patients with tailored, proactive allergy management solutions.

ADDRESSING CLIMATE CHANGE IN ALLERGY CARE

DR THIERRY BATARD, PRINCIPAL SCIENTIST

“We are expanding our research efforts to address the impact of climate change and environmental factors on allergic diseases. This includes scientific leadership in the field, notably through a dedicated special issue on the impact of climate change in allergy and AIT in *Exploration of Asthma and Allergy*. In addition, we have initiated a new collaboration with the University of Lille (France) to investigate the influence of environmental parameters on pollen characteristics, with the objective of improving our understanding of how changing environmental conditions may affect allergen exposure and disease outcomes.”

“We are expanding our research efforts to address the impact of climate change and environmental factors on allergic diseases.”



REGULATORY PROGRESS: SECURING PRODUCT AVAILABILITY ACROSS MARKETS

Regulatory achievements in 2025 were instrumental in maintaining and expanding patient access to our products across diverse markets. Our regulatory affairs teams navigated complex requirements whilst advancing multiple initiatives

simultaneously.

Key accomplishments included submissions for new market registrations in EMEA territories, and continued progress on regularisation processes. In France, our treatments are among the first AIT products

to undergo the new regularisation pathway. In Spain, we submitted our first wave of applications on schedule. These regulatory advances ensure continued product availability whilst positioning us favourably for future market expansion.

TECHNICAL AND PHARMACEUTICAL OPERATIONS: DELIVERING EXCELLENCE



ACROSS OUR NORTH AMERICAN AND EUROPEAN TECHNICAL AND PHARMACEUTICAL OPERATIONS, A CAREFULLY ORCHESTRATED STRATEGIC ROADMAP IS DRIVING AMBITIOUS GROWTH TARGETS. THIS TRANSFORMATION REPRESENTS MORE THAN EXPANSION. IT EMBODIES A FUNDAMENTAL RETHINKING OF HOW OPERATIONS CAN ACHIEVE EXCELLENCE THROUGH STANDARDISATION, PROCESS OPTIMISATION, SUSTAINABLE INVESTMENTS AND INTERNATIONAL COLLABORATION FOR THE BENEFIT OF THE PATIENTS AND HEALTHCARE PROFESSIONALS WE SERVE.

DELIVERING RESULTS WHILST TRANSFORMING

The challenge of transforming technical operations whilst maintaining delivery commitments is made possible through our disciplined approach that never loses sight of operational fundamentals as we pursue ambitious change.

On-Time In-Full delivery rates consistently exceeded 96% in 2025. Quality key performance indicators remained on target across all sites, with strong collaboration between our North American and French sites to assure best practices.

96%+
on-time in-full
delivery rates



99%
forecast
accuracy

Quality
targets
exceeded
across all
sites



OPERATING AT THE INTERSECTION OF SCIENCE AND SCALE

Across our sites, our Production, Quality Control and Quality Assurance teams are fully mobilised to sustain the pace required to deliver high-quality products at scale.

What makes our operations unique is the breadth of technologies we manage every day: from biological source materials to active substances, bulk allergens, named patient products and fully standardised specialty products. Operating this end-to-end model requires

strong scientific discipline, precise process control and deep analytical expertise.

In 2025, we continued to build on this framework: upgrading equipment, strengthening analytical capabilities, refining control strategies and ensuring robust alignment with evolving regulatory expectations. These efforts are essential to delivering consistent, reliable treatments to patients worldwide and are a key pillar of our ongoing transformation journey.

ENGINEERING TOMORROW'S OPERATIONS

Our strategic roadmap is designed to enhance efficiency, capacity and sustainability in measurable ways.

1. Standardising and Automating the Supply Chain

In Antony (France), for example, we are fundamentally changing how we respond to market demand by shifting from make-to-order to make-to-stock operations, reviewing work processes and strengthening demand planning. This transition leverages our existing SAP systems whilst preparing for next-generation enterprise capabilities. In parallel, we are deploying a harmonised S&OP, demand planning and KPI framework creating a more resilient, data-driven and globally aligned supply chain.

Shan Chen, our S&OP Director, explains:

"We've strengthened demand planning and enhanced regional coordination. This ensures supply chain resilience built on data-driven insights rather than reactive decision-making. The result is a more agile operation capable of responding to market dynamics whilst maintaining the stability that pharmaceutical manufacturing demands."



2. Optimising Manufacturing Processes

Process optimisation has become a driver of competitive advantage. The focus on specification framework optimisation is enabling Stallergenes Greer to fully leverage manufacturing processes whilst securing quality performance through continuous improvement.

Manufacturing efficiency gains are being realised through improved yields and larger batch sizes for both tablet and liquid forms. And operational excellence is being deployed through flow studies, visual management systems and the digitalisation of KPI monitoring. This creates a more centralised view of environments and equipment, enabling faster decision-making and more effective resource allocation. These optimisation initiatives are being deployed across both European and U.S. operations.

Scaling Production

The impact is substantial: Staloral® Pack 5G production has scaled from 800,000 vials to 2 million vials annually, whilst in-house tablet production has increased from 2 million to 10 million tablets.



3. Investing in Sustainable Infrastructure

Our site master plans provide a common long-term vision for ensuring the transformation, regulatory robustness and sustainability of our industrial capabilities across both Europe and North America. This ambitious investment plan encompasses new packaging lines for pharmaceutical specialties, expansion of active pharmaceutical ingredients (API) capacities and raw material production, modernisation and expansion of utilities, cleanroom environments and critical GMP systems at our Lenoir (North Carolina, U.S.) facility. These investments are essential to maintain regulatory readiness, support future European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) expectations and secure the long-term license-to-operate for non-sterile, sterile and allergen manufacturing.

Particularly noteworthy is our approach to building and energy capacity extension in Antony (France). The conceptual design was completed this year, with basic design for flow optimisation scheduled for 2026. These efforts represent a fundamental rethinking of how production facilities can operate more sustainably.

Across both continents, investments are both growth- and compliance-driven, ensuring that our facilities continue to meet the highest international Good Manufacturing Practices (GMP) standards while preparing for future regulatory evolution.

Sustainable Growth

Sustainability is embedded in our technical operations. Production capacity enhancements are being delivered through more economical and efficient use of energy, water, electricity and machinery, thus ensuring our growth is profitable, responsible and sustainable.

4. Fostering Transatlantic Collaboration

A major achievement in 2025 is the strategic harmonisation between French and U.S. technical and pharmaceutical operations. This goes beyond sharing best practices to pooling of expertise and knowledge transfer.

The harmonisation of KPIs between the Antony (France) and Lenoir (North Carolina, U.S.) facilities represents another dimension of this collaboration. By enabling better performance benchmarking and operational alignment across the Atlantic, we are creating a truly integrated global operation.

Transatlantic Integration in Action

Our new manufacturing unit at our Amilly (France) site processes cat hair and produces cat dander extracts for strategic allergen products. This initiative involves process transfer collaboration with our Lenoir (North Carolina, U.S.) facility and pooling competencies to secure the supply of critical raw materials. Similarly, we are harmonising manufacturing processes for house dust mite allergen production, with knowledge transfer between sites ensuring consistent quality and efficiency.

BUILDING FOR 2030 AND BEYOND

Transformation of this scale and ambition requires continued evolution. By integrating operational excellence with strategic vision and combining standardisation, automation, sustainable infrastructure investment and international collaboration Stallergenes Greer is laying the foundations to achieve our 2030 ambitions.

Our commitment to sustainability ensures growth will be responsible and resilient, while our clear roadmap provides confidence that our products and capabilities will evolve to meet emerging market needs and patient demand.

RESPONSIBILITY

CARE BEYOND ALLERGY



SOCIETY

“Patient needs drive our innovation to fight against all kinds of allergies”



ENVIRONMENT

“We are committed to advancing climate action and preserving nature to boost the prevention and treatment of allergies”



SOCIAL

“Investing in our people and empowering them to unleash their full potential”



GOVERNANCE


“Building trust with our stakeholders every day”



Environmental, Social and Governance: 2025 Progress Report

In 2025, Stallergenes Greer launched several major projects to structure its Environmental, Social and Governance (ESG) approach, ensure responsible practices throughout its value chain and reduce its environmental footprint.

The double materiality matrix, which maps the 28 material issues identified in 2024, has been audited and validated by a third-party organisation. These issues were determined based on Stallergenes Greer's positive or negative, actual or potential impacts on the environment and society, as well as the impact of these issues on the Group's financial performance.



To address the most significant issues, a 2025-2027 ESG roadmap has been defined, combining global targets for water and carbon with joint efforts across departments for industrial site initiatives.

Furthermore, Stallergenes Greer has strengthened its governance with the creation of an ESG Steering Committee and the integration of ESG into key projects, notably industrial transformation projects related to Technical Operations. The Group is also continuing its efforts towards responsible purchasing and the assessment of suppliers in terms of integrity, environmental practices and human rights.

Finally, Stallergenes Greer has developed carbon and water transition plans and defined reduction trajectories for 2027 and 2030 incorporating growth perspectives, initially focused on our industrial sites:

- 7% Greenhouse Gas (GhG) emissions in 2027 and -20% in 2030 on Scopes 1 and 2 compared to 2023,
- 3% water consumption in 2027 and -19% in 2030 compared to 2024

The trajectories and transition plans have been approved by the Group's Leadership Team, and a number of actions have already been implemented.

Examples of actions to reduce GhG emissions:

- Replacement of chillers,
- Shutting down air handling units outside production hours,
- Electrification of the vehicle fleet,
- Installation of Water-Cooled Air Compressors (WHR),
- Recovery of waste heat for hot water production.

Examples of actions to reduce water consumption:

- Replacement of two washers,
- Installation of a pressurised steam generator,
- Centralisation of softened and purified water production,
- Replacement of the water for injection production system.

Measuring Progress

Stallergenes Greer's 12 key performance indicators (KPI) provide an objective and transparent basis for measuring progress toward our 2030 corporate responsibility ambition. 2025 marks the second year of reporting on these KPIs which reflect our commitment to sustainability.

SOCIETY

2030 Ambitions	2024 KPI	2025 KPI
Extend access to, and use of, Stallergenes Greer AIT products	<ul style="list-style-type: none"> 8 active educational programmes either sponsored or supported by unrestricted educational grants: EAACI: 4 modules, AIT module, New insights in AIT module, 2 MOOC on OMIC technologies in allergy research, Karger, accredited CME course on the use of AIT in respiratory allergy, Xpeer, accredited CME course on AIT basics, Medscape, accredited CME roundtable on how to identify patients in need of AIT and optimise patient outcomes, Go Beyond AIT training programme 	<ul style="list-style-type: none"> 8 active educational programmes either sponsored or supported by unrestricted educational grants: EAACI: 4 modules, AIT module, New insights in AIT module, 2 MOOC on OMIC technologies in allergy research, Xpeer: 3 accredited courses : <ul style="list-style-type: none"> accredited CME course on AIT basics accredited CME course on AIT and adherence accredited CME course on AIT advanced Go Beyond AIT training programme
	10 publications and 21 abstracts	9 publications and 25 abstracts
	More than 1.3 million patients treated with Stallergenes Greer products	More than 1.3 million patients treated with Stallergenes Greer products
Increase the production capacity of our new sublingual specialty production line each year	Automated packaging line in Antony (France) packaged 50% of total SLIT vials, 100% of which are for export	Automated packaging line in Antony (France) packaged 29% of total SLIT vials, 100% of which are for export. Compared to last year, the automated packaging line produced 41% more SLIT vials.
Empower patients by integrating their voice in our initiatives	<p>Three surveys/studies led with patient community:</p> <ul style="list-style-type: none"> Online cat SLIT treatment survey in France to gain understanding of socio-demographic characteristics, living environment and cat exposure, allergy history and management, and perception of SLIT impact. 197 responders 45-minute interviews with 15 patients/ caregivers in the U.S. to understand attitudes, experiences and unmet needs with respect to SCIT treatment SPEED survey in France for patients undergoing cat or house dust mite AIT, with or without using I PUMP®, regarding proper use and observance (400 patients) 	Study led with patient community: Stallergenes Greer led a working group in 2025 with 10 German and French expert patients to discuss the difficulties associated with their respiratory allergies and treatments. We worked together to develop solutions.

ENVIRONMENT

2030 Ambitions	2024 KPI	2025 KPI
Ensure that volume growth until 2030 will be delivered by reaching efficiencies on water consumption at the Antony and Lenoir sites	Water consumption at the Antony and Lenoir sites has been measured, and reduction levers are being explored	Water consumption at the Antony and Lenoir sites has been measured and a reduction action plan has been initiated. 2025 : Water consumption m ³ <ul style="list-style-type: none"> Antony : 74 770 m³ Lenoir : 20 364 m³
Reduce our GhG emissions (scope 1, 2, 3) compared to baseline	Assessment of our 2023 GhG emissions: 19,983 tCO ₂ e across France and the U.S. Our carbon transition plan is in progress	Our GhG emissions assessment will be conducted again in 2026. Our transition plan is on track, and we are currently working specifically on Scope 3.
An eco-friendly pack pilot for sublingual specialty available for implementation in manufacturing by 2025	In progress. The pilot is expected to be available by year-end 2025	The project is still ongoing: the pilot has been carried out with a view to commissioning in the coming months.

SOCIAL

2030 Ambitions	2024 KPI	2025 KPI
Maintain the injury frequency rate at less than or equal to 3.5	2024: 3.47	2025: 3.21
Increase every other year employee satisfaction as measured by wellbeing survey	2024 wellbeing survey: <ul style="list-style-type: none"> Participation rate: 68% Employee satisfaction rate: 73% 	The survey is conducted every two years and will therefore be carried out in 2026. By 2025, 100% of the actions identified following the 2024 survey had been implemented.
100% of employees will have followed training and e-learning annually (excluding mandatory trainings by law) by 2030	2024: 97% (96% in 2023)	2025: 98% (97% in 2024)

GOVERNANCE

2030 Ambitions	2024 KPI	2025 KPI
Expand each year the coverage of corporate responsibility assessments of our active supplier database	99% of active suppliers assessed using the Ecovadis IQ-Plus module	100% of eligible suppliers added to IQ PLUS (1,434)
	Onboarding of 250 suppliers with the RATING module	Onboarding of 361 suppliers with the RATING module

STALLERGENES GREER FOUNDATION



THE STALLERGENES GREER FOUNDATION CONTINUES TO CHAMPION INNOVATION AND PATIENT-CENTERED APPROACHES, FULFILLING ITS MISSION TO “CREATE HEALTHIER FUTURES FOR ALL.”

THE FOUNDATION, UNDER THE AEGIS OF THE FONDATION DE FRANCE, IS DEDICATED TO ADVANCING ALLERGY RESEARCH, FOSTERING ACADEMIC EXCELLENCE AND ADDRESSING ENVIRONMENTAL FACTORS WHICH IMPACT ALLERGIES. WITH ITS COMMITMENT TO EXCELLENCE AND INNOVATION, THE FOUNDATION BRIDGES SCIENCE, MEDICINE AND PATIENT ADVOCACY.

The foundation is governed by a Board of Trustees which brings together the Managing Board and the Scientific Board.

MANAGING BOARD

The Managing Board is composed of four Stallergenes Greer executive officers:

- Dominique Pezziardi, Chairman.
- Dr Silvia Scurati, Scientific Director.
- Dr Laurent Mascarell, Innovation Director.
- Catherine Kress, Secretary General.

SCIENTIFIC BOARD

The Scientific Board is composed of four independent members:

- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France).
- Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome (Italy).
- Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology -Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon).
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.).

SCIENCE AWARDS FOR ALLERGY

In 2023, the Stallergenes Greer Foundation launched its Science Awards for Allergy. These awards recognise outstanding contributions to allergy research, patient engagement and environmental health initiatives.

The 2025 edition will honour contributions in two categories:


Innovation in Allergy Treatment Award

The award recognises cutting-edge research with clinical relevance in the field of allergy. It will support projects with practical outcomes and applications, which deepen knowledge of allergy treatments and inspire young researchers and clinicians. The award is expected to facilitate the implementation of innovative approaches in allergy care particularly in the areas of prevention, intervention and research.

Patient Commitment Award

This award recognises projects which integrate the perspectives of patients with allergies, as well as those of their family, foster knowledge of allergic diseases and treatments, and develop the understanding of unmet needs to improve allergy care for all. The work must contribute to better understanding, preventing and treating environmental or food allergy diseases.

Recipients of the 2025 Science Awards for Allergy will be announced in 2026.



PRODUCTS AND PORTFOLIO

OUR PRODUCTS

STALLERGENES GREER SUPPORTS PHYSICIANS SPECIALISED IN ALLERGY AND PATIENTS AT EACH STAGE OF ALLERGEN IMMUNOTHERAPY (AIT) TREATMENT. OUR COMPREHENSIVE AND CONSISTENT PORTFOLIO IS ADAPTED TO THE INDIVIDUAL NEEDS AND PROFILE OF EACH PATIENT AND COVERS A BROAD VARIETY OF ALLERGENS.



A Personalised and Standardised Treatment Offering

Stallergenes Greer believes one solution does not fit all patients, hence we provide patients with personalised treatment options that are tailored to their individual needs. We aim to offer a comprehensive portfolio of AIT treatments globally which allow patients and their physicians to determine the administration method that best meets the disease and lifestyle needs of the patient.

The Group's allergen extracts cover a vast array of allergens. They can be produced in standardised form and can also be tailored to the specific needs of patients in terms of composition, concentration, and dosage.

These personalised solutions, known as Named Patient Products (NPPs), are prepared according to the physician's prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollens, house dust mites, moulds...). Each NPP has its own biological activity and is prepared for the unique needs of the individual patient.

Quality and Innovation

Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, Stallergenes Greer's innovative diagnostic tools and AIT solutions are designed to improve ease of access and treatment outcomes.

Whatever the options, Stallergenes Greer's diagnostic and AIT treatments meet the most stringent clinical criteria, quality standards and health authorities' regulatory requirements.

OUR PRODUCT PORTFOLIO

RESPIRATORY ALLERGY TREATMENTS

Sublingual

Staloral® (oral solution)

For the treatment of allergy involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate) of a seasonal or perennial nature, in adults and children (from the age of 5).

Actair® / Orylmyte® / Aitmyte® (tablet)

For the treatment of house dust mite allergies involving rhinitis, with or without conjunctivitis, in adults and adolescents over the age of 12 (and under 12 years of age in certain territories).

Oralair® / Aitgrys® (tablet)

For the treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents, and children (above the age of 5). Oralair® is a five grass (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) mixture, which represents many of the natural exposure and sensitisation conditions of grass pollen allergic patients.

Subcutaneous Immunotherapy

Alustal®

For the treatment of allergic rhinitis, allergic rhinoconjunctivitis or mild to moderate asthma in adults and children (from the age of 5).

Bulk allergens for use by healthcare professionals



Not all our products and extracts are available in all geographic territories.

VENOM ALLERGY TREATMENTS

Subcutaneous Immunotherapy

Albey® venom

For the treatment of allergy to honeybee, wasp and yellow jacket venoms.

VETERINARY SOLUTIONS

From allergen testing to making precision treatment medicines, Stallergenes Greer is committed to providing veterinary specialists with products that can help treat animal allergies.

In the U.S., Stallergenes Greer offers a comprehensive range of allergen extracts and supplies for veterinary dermatologists to support the needs of their clients and pet patients.

Veterinary dermatologists are veterinarians that have specialised training in the management of allergic disease. They may use products from companies like Stallergenes Greer to compound named patient allergy products for dogs, cats, horses and more. Stallergenes Greer produces extracts of different strengths and formulations specifically for veterinary specialists.

EXTRACTS, DIAGNOSTIC TESTS AND SUPPLIES

Stallergenes Greer manufactures a broad portfolio of allergen extracts, diagnostic tests and supplies.

CONNECTED ASSISTANT

iPUMP®

Designed to improve treatment adherence and optimise outcomes for patients undergoing sublingual solution AIT treatment.

OUR PORTFOLIO

Not all of our products and extracts are available in all geographic territories.

1/ SUBLINGUAL PRODUCTS

The allergens and concentrations available vary by market.
Allergens:

MITES
D. pteronyssinus
D. Farinae
D.pte / D.far 50/50
Blomia / D.pte / D.far

GRASSES
5 Grasses
Cocksfoot
Bermuda Grass

TREES
Birch
Ash
Alder
Hazel
Olive
2 Trees Mix (Ash / Olive)
3 Trees Mix
(Alder / Birch / Hazel)
Cupressaceae
Birch / Timothy Mix

DANDER
Cat epithelia
Cat IR300

WEEDS
Ragweed
Wall pellitory
Mugwort

MOULDS
Alternaria

POLLEN MIX
Birch / Ash
5 Grasses / Olive
5 Grasses / Birch
5 Grasses / Rye
5 Grasses / Juniperus
5 Grasses / Ash
5 Grasses / Berm. Grass
5 Grasses / 3 trees
5 Grasses / Ragweed
Birch / Timothy
Olive / Ash
Ragweed / Mugwort
5 Grasses / Mugwort
5 Grasses / Cynodon

ORALAIR® / AITGRYS®

A five grass pollen mixture composed of Cocksfoot (*Dactylis glomerata L.*), Sweet vernal grass (*Anthoxanthum odoratum L.*), Rye grass (*Lolium perenne L.*), Meadow grass (*Poa pratensis L.*) and Timothy (*Phleum pratense L.*).

ACTAIR® / ORYLMYTE® / AITMYTE®

A house dust mite (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*) mixture.

2/ SUBCUTANEOUS PRODUCTS

ALUSTAL® ALBEY® VENOM

3/ VETERINARY PRODUCTS

VET EXTRACTS

Allergens:

TREES & SHRUBS

Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona
Ash, Oregon
Ash, Red/Green
Ash, White
Aspen
Bayberry/Was Myrtle
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt/Tamarisk
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Fremont
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar/Fall Blooming
Elm, Siberian
Eucalyptus
Hackberry
Hazel, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona/Gambel
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water

Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pepper Tree
Pine, Australian
(Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia/Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy
Poplar, White
Privet, Common
Sweet Gum
Sycamore, American/
Eastern
Sycamore, Western
Walnut, Black
Walnut, California Black
Walnut, English
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Ash Mix
Birch Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Maple-Box Elder Mix
Pine Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix
Daisy Ox-Eye
Dandelion
Sunflower
Alfalfa
Mustard
Red Clover
Sugar Beet

GRASSES
Bahia Grass
Bermuda
Brome Grass, Smooth
Canarygrass
Corn, Cultivated
Couch/Quack Grass
Johnson Grass
Kentucky Blue/June
Meadow Fescue
Oats, Common/Cultivated
Orchard
Redtop

RYE, CULTIVATED
Ryegrass, Giant Wild
Ryegrass, Italian
Ryegrass, Perennial
Sweet Vernal
Timothy
Velvetgrass
Wheat Cultivated
Wheatgrass, Western
7 Grass Mix
9 Southern Grass Mix
Bermuda-Johnson Grass
Mix
K-O-R-T Grass Mix

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
Moth
2 Cockroach Mix
4 Insect Mix

FUNGI & SMUTS
Acremonium strictum
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Drechslera spicifera
Epicossium nigrum
Epidermophyton floccosum
Fusarium moniliforme
Fusarium solani
Geotrichum candidum
Gliocladium viride
Helminthosporium solani
Malassezia pachydermatis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum (notatum)
Penicillium digitatum
Phoma betae
Rhizopus oryzae
Rhizopus stolonifer
Rhodotorula mucilaginosa var. mucilaginosa
Saccharomyces cerevisiae
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes

WEEDS
Allscale
Baccharis
Burrobrush
Careless Weed, Amaranth/
Green
Cocklebur
Dock, Yellow/Curly
Dog Fennel
Firebush/Kochia
Goldenrod
Hemp, Water
Iodine Bush
Lamb's Quarter
Lenscale/Quailbrush
Marsh Elder, Burweed/
Giant Poverty
Marsh Elder, True/Rough
Mugwort, Common
Mugwort, Darkleaved/
Sagebrush, Prairie
Nettle
Palmer's Amaranth
Ragweed, Rough/Redroot
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant
Ragweed, Short
Ragweed, Slender
Ragweed, Southern
Ragweed, Western

Russian Thistle
Sagebrush, Common
Saltbush, Annual
Sorrel, Sheep/Red
Wingscale
3 Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Ragweed Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

GRASSES
Bahia Grass
Bermuda
Brome Grass, Smooth
Canarygrass
Corn, Cultivated
Couch/Quack Grass
Johnson Grass
Kentucky Blue/June
Meadow Fescue
Oats, Common/Cultivated
Orchard
Redtop

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
Moth
2 Cockroach Mix
4 Insect Mix

FUNGI & SMUTS
Acremonium strictum
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Drechslera spicifera
Epicossium nigrum
Epidermophyton floccosum
Fusarium moniliforme
Fusarium solani
Geotrichum candidum
Gliocladium viride
Helminthosporium solani
Malassezia pachydermatis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum (notatum)
Penicillium digitatum
Phoma betae
Rhizopus oryzae
Rhizopus stolonifer
Rhodotorula mucilaginosa var. mucilaginosa
Saccharomyces cerevisiae
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes

WEEDS
Allscale
Baccharis
Burrobrush
Careless Weed, Amaranth/
Green
Cocklebur
Dock, Yellow/Curly
Dog Fennel
Firebush/Kochia
Goldenrod
Hemp, Water
Iodine Bush
Lamb's Quarter
Lenscale/Quailbrush
Marsh Elder, Burweed/
Giant Poverty
Marsh Elder, True/Rough
Mugwort, Common
Mugwort, Darkleaved/
Sagebrush, Prairie
Nettle
Palmer's Amaranth
Ragweed, Rough/Redroot
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant
Ragweed, Short
Ragweed, Slender
Ragweed, Southern
Ragweed, Western

Trichophyton rubrum
Trichothecium roseum
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Corn Smut
Grain Smut mix
Grass Smut Mix

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
Moth
2 Cockroach Mix
4 Insect Mix

DUST & DUST MITES
Dust, House
Grain Mill Dust Mix
Acarus siro
Blomia tropicalis
Dermatophagoides farinae
Dermatophagoides pteronyssinus
Lepidoglyphus destructor
Tyrophagus putrescentiae
Equal Parts Mixture

VET OTHER SUPPLIES

STERILE DILUENTS

NONSTERILE EMPTY VIALS

STERILE EMPTY VIALS

PLASTIC COLORED CAPS

VIAL RACKS

AMBER VIALS AND METERED PUMPS

SYRINGES AND SYRINGE TRAYS

ANCILLARY PRODUCTS

4/ STANDARDISED HUMAN EXTRACTS

STANDARDISED CAT HAIR

STANDARDISED DERMATOPHAGOIDES FARINA MITE

STANDARDISED DERMATOPHAGOIDES PTERONYSSINUS MITE

STANDARDISED MITE MIX

STANDARDISED GRASS & POLLENS

Bermuda Grass
Kentucky Blue/June
Meadow Fescue
Orchard
Redtop
Ryegrass, Perennial
Sweet Vernal
Timothy
7 Grass Mix
K-O-R-T Grass Mix
K-O-R-T and Sweet Vernal Mix
K-O-T Grass Mix
Timothy/Orchard Grass Mix
T-O-S Grass Mix
Ragweed, Short
National Weed Mix
Ragweed Mix

POLLENS - TREES & SHRUBS

Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona (Velvet)
Ash, Green
Ash, Oregon
Ash, White
Aspen
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt (Tamarisk)
Cottonwood, Arizona (Fremont)
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Siberian
Eucalyptus, Bluegum
Hackberry
Hazel, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed

POLLENS - WEEDS

Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot

Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite, Velvet
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona (Gambel)
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy's
Poplar, White
Privet
Sweetgum
Sycamore, American
Sycamore, California (Western)
Walnut, Black
Walnut, California Black
Walnut, English
Wax Myrtle
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Birch Mix
Central/Eastern 4 Tree Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 9 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory-Pecan Mix
Hickory-Pecan Mix
Juniper Mix
Maple-Box Elder Mix
Peppertree Mix
Pine Mix
Western 3 Tree Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix

POLLENS - GRASSES
Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS

Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Curvularia spicifera
Epicossium nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gibberella fujikuroi
Gliocladium viride
Helminthosporium solani
Hypomyces perniciosus
Microsporium canis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum var. chrysogenum
Penicillium digitatum
Phoma betae
Rhizopus arrhizus
Rhizopus stolonifer
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Sarcocladium strictum
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
AHH Mix
Alternaria/Hormodendrum Mix
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor Mix
New Stock Fungi Mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Bermuda Grass Smut
Corn Smut
Loose Smut of Barley

POLLENS - FLOWERS & PLANTS
Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS
Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot

Pigweed, Spiny
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant (Tall)
Ragweed, Lanceleaf
Ragweed, Slender
Ragweed, Western
Russian Thistle
Sagebrush, Common
Sage, Prairie
Saltbush, Annual
Sorrel, Sheep (Red)
Waterhemp, Tall
Wingscale
3 Weed Mix
Baccharis Mix
Central/Western Weed Mix
Common Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

POLLENS - GRASSES
Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS

Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Curvularia spicifera
Epicossium nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gibberella fujikuroi
Gliocladium viride
Helminthosporium solani
Hypomyces perniciosus
Microsporium canis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum var. chrysogenum
Penicillium digitatum
Phoma betae
Rhizopus arrhizus
Rhizopus stolonifer
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Sarcocladium strictum
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
AHH Mix
Alternaria/Hormodendrum Mix
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor Mix
New Stock Fungi Mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Bermuda Grass Smut
Corn Smut
Loose Smut of Barley

POLLENS - FLOWERS & PLANTS
Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS
Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot

Loose Smut of Wheat
Oat Smut
Grain Smut Mix
Grass Smut Mix

EPITHELIA
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Canary Feathers
Chicken Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flax
Gum Arabic
Gum Karaya
Gum Tragacanth
Kapok
Leaf Tobacco, Cultivated
Orris Root
Pyrethrum
Silk Worm Cocoon
Ant, Black Carpenter
Fire Ant – Solenopsis richteri
Fire Ant – Solenopsis invicta
Cockroach, American*
Cockroach, German*
Deer Fly
Flea (Aqueous Only)
House Fly
Mosquito
2 Cockroach Mix

POLLENS - GRASSES
Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS

Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Curvularia spicifera
Epicossium nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gibberella fujikuroi
Gliocladium viride
Helminthosporium solani
Hypomyces perniciosus
Microsporium canis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum var. chrysogenum
Penicillium digitatum
Phoma betae
Rhizopus arrhizus
Rhizopus stolonifer
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Sarcocladium strictum
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
AHH Mix
Alternaria/Hormodendrum Mix
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor Mix
New Stock Fungi Mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Bermuda Grass Smut
Corn Smut
Loose Smut of Barley

POLLENS - FLOWERS & PLANTS
Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS
Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot

Beef
Lamb
Pork
Chicken Meat
Egg White, Chicken
Egg Whole, Chicken
Egg Yolk, Chicken
Turkey Meat
Milk, Cow
Bass, Black
Catfish, Channel
Clam, Northern Quahog
Cod, Atlantic
Crab, Blue
Flounder, Southern
Lobster, American
Mackerel, King/Atlantic
Oyster, Atlantic/Eastern
Perch, Ocean
Salmon, Atlantic
Scallops, Sea
Shrimp, Brown
Trout, Rainbow
Tuna, Yellowfin
Fish, Mix
Shellfish Mix
Almond
Brazil Nut
Cashew Nut
Coconut
Hazelnut (Filbert)
Peanut
Pecan
Walnut, Black
Walnut, English

5/ PRICK TESTS

40-WELL SKIN OMNI™ EVALUATION PACKAGE

40-WELL GREER® PICK® EVALUATION PACKAGE

60-WELL SKIN OMNI™ EVALUATION PACKAGE

60-WELL GREER® PICK® EVALUATION PACKAGE

ALYOSTAL PRICK®

Positive control (Histamin)
Negative control
D. Pteronyssinus
D. Farinae
5 Grasses
Birch
Ragweed
Hazel
Olive
Cupressaceae
Cat dander
Mugwort
Alder
Ash
Wall pellitory
Blomia
Cynodon
Rye grass
Grapefruit
Alternaria
Artemisia
Bermuda grass
Latex

GREER® PICK®

GREER® PICK® TRAY™

GREER® PICK® TRAY™

LID PRICK LANCET®

STALLERPOINT®

GREER® PICK® WELL™

SKINTESTOR OMNI™

SKINTESTOR OMNI™

SKINTESTOR OMNI™

SKINTESTOR OMNI™

TRAYS

THE GREER® PICK®

SYSTEM

6/ OTHER SUPPLIES

DOM' HOUS®

GREER® STERILE DILUENTS™

GREER® STERILE EMPTY VIALS™

GREER® VERSA VIAL RACK

ANCILLARY PRODUCTS

GREER PHARMACY – NAMED PATIENT PRODUCTS

IPUMP®

STALLERGENES GREER
INTERNATIONAL AG
Zugerstrasse 32
6340 Baar, Switzerland

This report contains information about Stallergenes Greer's worldwide business. Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

2025 In Review is available on the Group's website www.stallergenesgreer.com

CONCEPTION AND EDITORIAL FOLK FORMAN, 68 rue de la Chaussée d'Antin, 75009 Paris, FRANCE

www.folkforman.com

CREATION AND PRODUCTION MPG VISUAL DESIGN, PO Box 1002, Manzanita, OR 97130, USA

www.mpgvisualdesign.com

PHOTO CREDITS All rights reserved - Vika Strawberrika/Unsplash (cover)- Gérard Uféras (p 3, 6, 8, 23, 26, 27, 28, 42, 43, 48) - Jeanyves Verdu (p 3, 5, 13, 14, 16, 20, 29, 30, 31, 34, 35, 37, 52, 56, 57) - John Bailey (p 3, 26, 43, 46, 47, 57, 60) - Getty Images (p 5) - SG (p 12, 13, 16, 25, 26, 43, 44) - Anthony Voisin (p 22, 24, 44) - Fernanda Martinez/Unsplash (p 31) - Josh Palmer (p 45) - Douglas Fry (p 27) - IMPEESA production (p 38-39)



Printed in France by Noël Imprimeur Paris - Imprim'Vert® certified printer - on paper from sustainable forests in an ISO 14001 and EMAS certified facility.
Completed April 25, 2026.

Thank you to all patients, healthcare professionals and Stallergenes Greer employees who appear in this publication.

Palforzia®: © 2025, Société des Produits Nestlé S.A. or its affiliates.

All other product names listed in this document are registered trademarks of the Stallergenes Greer group.

Produced by Stallergenes Greer, Global Communications

Follow us on



www.linkedin.com/company/stallergenesgreer



x.com/StallergenesCom

**STALLERGENES GREER
INTERNATIONAL AG**
Zugerstrasse 32
6340 Baar, Switzerland